US 11,939,367 B2
BTLA fusion protein agonists and uses thereof
Carl F. Ware, Solana Beach, CA (US); John Sedy, San Diego, CA (US); Tigran Aivazian, San Diego, CA (US); Brian Miller, San Diego, CA (US); and Natasha K. Crellin, San Carlos, CA (US)
Assigned to Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US); and Pfizer Inc., New York, NY (US)
Filed by Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US); and PFIZER INC., New York, NY (US)
Filed on Mar. 1, 2021, as Appl. No. 17/188,912.
Application 17/188,912 is a division of application No. 15/737,259, granted, now 10,961,297, previously published as PCT/US2016/040108, filed on Jun. 29, 2016.
Claims priority of provisional application 62/187,105, filed on Jun. 30, 2015.
Prior Publication US 2022/0025017 A1, Jan. 27, 2022
Int. Cl. C07K 14/705 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); C07K 14/71 (2006.01); C07K 14/715 (2006.01); C07K 19/00 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/71 (2013.01) [A61K 38/17 (2013.01); A61K 38/177 (2013.01); A61K 38/1793 (2013.01); A61K 45/06 (2013.01); A61K 47/68 (2017.08); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 14/715 (2013.01); C07K 19/00 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)] 17 Claims
 
1. A method of treating graft versus host disease comprising administering a fusion protein to a subject in need thereof,
wherein the fusion protein comprises a human herpesvirus entry mediator (HVEM) protein comprising amino acids 1-202, 1-184, 39-202, or 39-184 of SEQ ID NO: 2 and an Fc protein, and
wherein the human HVEM protein comprises mutations S58R, G68T, L70W, and L90A with reference to SEQ ID NO: 2.